PDF(Sci-hub)
Abstract：
Monoamine oxidase inhibitors (MAOIs) were the first class of modern antidepressants; however, they are under-utilized as compared to the newer antidepressants.
In this systematic review, network meta-analysis was used to investigate the comparative efficacy and acceptability of MAOIs for depressive disorders. Overall, the network meta-analysis included 52 double-blind, randomized controlled trials (RCTs) that compared 14 antidepressants or placebo. Across studies, the mean arm size was n = 58 participants from a total N = 6462 (5309 active drug; 1153 placebo).
Except fluvoxamine, all antidepressants demonstrated superior efficacy to placebo, and none demonstrated substantially better or worse all-cause dropout rates. Phenelzine demonstrated superior evidence for efficacy compared to all other treatments, and clomipramine demonstrated superior evidence for acceptability compared to all other treatments.
The study is primarily limited by low estimate precision due to a relative paucity of studies for some of the included treatment conditions. Further evidence is required to study the relative efficacy of MAOIs against newer antidepressants.
The results of this analysis largely support the re-evaluation of the use of MAOIs as antidepressant agents in the treatment algorithm of depression.
In this systematic review, network meta-analysis was used to investigate the comparative efficacy and acceptability of MAOIs for depressive disorders. Overall, the network meta-analysis included 52 double-blind, randomized controlled trials (RCTs) that compared 14 antidepressants or placebo. Across studies, the mean arm size was n = 58 participants from a total N = 6462 (5309 active drug; 1153 placebo).
Except fluvoxamine, all antidepressants demonstrated superior efficacy to placebo, and none demonstrated substantially better or worse all-cause dropout rates. Phenelzine demonstrated superior evidence for efficacy compared to all other treatments, and clomipramine demonstrated superior evidence for acceptability compared to all other treatments.
The study is primarily limited by low estimate precision due to a relative paucity of studies for some of the included treatment conditions. Further evidence is required to study the relative efficacy of MAOIs against newer antidepressants.
The results of this analysis largely support the re-evaluation of the use of MAOIs as antidepressant agents in the treatment algorithm of depression.
摘要：
单胺氧化酶抑制剂（MAOIs）是第一类现代抗抑郁药；然而，与较新的抗抑郁药相比，它们的利用率不足。
在这篇系统综述中，采用网络荟萃分析研究MAOIs对抑郁障碍的比较疗效和可接受性.总的来说,网络荟萃分析包括52名双盲，比较14种抗抑郁药或安慰剂的随机对照试验（RCT）。在整个研究中，在总共N=6462例(5309种活性药物;1153种安慰剂)中,平均手臂大小为n=58例.
除了氟伏沙明,所有抗抑郁药均表现出比安慰剂更好的疗效，没有人表现出明显更好或更坏的全因辍学率。与所有其他治疗方法相比，苯乙嗪表现出更好的疗效证据，与所有其他治疗方法相比，氯米帕明和氯米帕明表现出更好的可接受性证据。
该研究主要受到低估计精度的限制，这是由于对一些所包括的治疗条件的研究相对缺乏。需要进一步的证据来研究MAOIs对新型抗抑郁药的相对功效。
该分析的结果在很大程度上支持了对MAOIs作为抗抑郁药在抑郁症治疗方案中使用的重新评估。
在这篇系统综述中，采用网络荟萃分析研究MAOIs对抑郁障碍的比较疗效和可接受性.总的来说,网络荟萃分析包括52名双盲，比较14种抗抑郁药或安慰剂的随机对照试验（RCT）。在整个研究中，在总共N=6462例(5309种活性药物;1153种安慰剂)中,平均手臂大小为n=58例.
除了氟伏沙明,所有抗抑郁药均表现出比安慰剂更好的疗效，没有人表现出明显更好或更坏的全因辍学率。与所有其他治疗方法相比，苯乙嗪表现出更好的疗效证据，与所有其他治疗方法相比，氯米帕明和氯米帕明表现出更好的可接受性证据。
该研究主要受到低估计精度的限制，这是由于对一些所包括的治疗条件的研究相对缺乏。需要进一步的证据来研究MAOIs对新型抗抑郁药的相对功效。
该分析的结果在很大程度上支持了对MAOIs作为抗抑郁药在抑郁症治疗方案中使用的重新评估。
